Antitrypanosomal therapy for chronic Chagas' disease [2]

New England Journal of Medicine

Volumn 365, Issue 13, 2011, Pages 1258-1259

  Bestetti, Reinaldo B ^a   Cardinalli Neto, Augusto ^a  

^a HOSPITAL DE BASE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

CHAGAS DISEASE; CHRONIC DISEASE; DISEASE COURSE; DISEASE TRANSMISSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART BUNDLE BRANCH BLOCK; HEART VENTRICLE WALL MOTION; HUMAN; LETTER; NEURITIS; PREGNANCY; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; ANIMAL; FEMALE; NOTE; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; FEMALE; HUMANS; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 80053379452     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1108653     Document Type: Letter

References (3)

1. Pazin-Filho A, Romano MM, Almeida-Filho OC, et al. Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications. Braz J Med Biol Res 2006;39:483-7.
2. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J 2008;156:422-30.
3. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53(15):e1-e90.